	US 12,215,109 B2
	Crystal of pyrazolo[3,4-d]pyrimidine
Tadashi Shimamura, Tsukuba (JP); and Hiromi Oshiumi, Tokushima (JP)
Assigned to TAIHO PHARMACEUTICAL CO., LTD., Chiyoda-ku (JP)
Appl. No. 17/271,424
Filed by TAIHO PHARMACEUTICAL CO., LTD., Chiyoda-ku (JP)
PCT Filed Aug. 28, 2019, PCT No. PCT/JP2019/033647 § 371(c)(1), (2) Date Feb. 25, 2021, PCT Pub. No. WO2020/045475, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 2018-159840 (JP), filed on Aug. 29, 2018.
Prior Publication US 2021/0332056 A1, Oct. 28, 2021
Int. Cl. C07D 487/04 (2006.01)

CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)]

8 Claims

1. A crystal of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-N-(4-(2-(dimethylamino)-2-oxoethyl)-2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide having an X-ray powder diffraction spectrum having at least six peaks at diffraction angles (2θ±0.2°) selected from the group consisting of 6.0°, 7.7°, 8.9°, 10.6°, 12.1°, 13.1°, 14.0°, 14.7°, 15.5°, 15.8°, 16.8°, 17.7°, 18.1°, 18.4°, 19.4°, 23.4°, 24.1°, 24.7°, 25.1° and 25.7°.